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An ideal biomarker for pneumonia should allow an early 
diagnosis and differential diagnosis from noninfectious 
conditions and should inform about the course and 
prognosis of the disease. Procalcitonin (PCT) covers 
these features better as compared to more commonly 
used biomarkers like C-reactive protein or leukocyte 
count. PCT complements and improves the assessment 
of pneumonia based on careful patient history, dedi-
cated physical examination, and appropriate cultures. 
Importantly, a PCT-based therapeutic strategy can safely 
and markedly reduce antibiotic courses in community-
acquired pneumonia. However, as is the cast with all 
diagnostic surrogate markers, PCT can be increased 
in noninfectious conditions and may remain low in 
bacterial infections, especially localized infections. This 
stresses the importance of follow-up measurements, 
because PCT levels in these patients often show a grad-
ual increase during follow-up. Although PCT is better 
than more common biomarkers for the prognosis of 
pneumonia and to predict survival and outcome, novel 
biomarkers show an even better prognostic accuracy.
Introduction
Procalcitonin (PCT) is a precursor peptide of the hormone 
calcitonin (CT) [1]. After translation from CT messenger 
RNA (mRNA), PCT is cleaved enzymatically into smaller 
peptides, finally yielding the 32 amino acid mature CT 
[2]. Most CT precursor peptides including PCT are found 
in the serum of healthy persons. 
Originally, mature CT was thought to be a hormone 
exclusively of thyroidal C-cell origin that played an 
important role in skeletal homeostasis [1]. However, 
provided that thyroid hormone is replaced, thyroidectomy 
in humans has no important pathologic consequences: 
calcium homeostasis remains intact, and bone density 
is not decreased [3,4]. The presence of the parathyroid 
gland and other evolutionary changes in tetrapods 
suggest that the function of the mature CT hormone in 
humans is no longer essential [5]. 
Conversely, a cytokine-like role in the host defense is 
likely. Accordingly, in microbial infections and various 
forms of inflammation, circulating levels of several CT 
precursors, including PCT but not mature CT, increase 
up to several-thousand–fold. This increase and especially 
the course correlate with mortality and the severity of the 
condition [6–9]. 
In the absence of infection, the extrathyroidal tran-
scription of the CALC-I gene is suppressed and restricted 
to a selective expression in neuroendocrine cells found 
mainly in the thyroid and lung. In these neuroendocrine 
cells, the mature hormone is processed and stored in 
secretory granules (Fig. 1) [10,11]. 
A microbial infection induces an ubiquitous increase 
of CALC-I gene expression and a constitutive release 
of PCT from all parenchymal tissues and differentiated 
cell types throughout the body [12]. The transcriptional 
expression of CT-mRNA is more uniformly upregulated 
in sepsis than are the mRNAs of the classical cytokines 
(eg, tumor necrosis factor–B and interleukin [IL]-6) 
[12]. Parenchymal cells (including liver, kidney, adipo-
cytes, and muscle) provide the largest tissue mass and 
principal source of circulating PCT in sepsis and infec-
tions [11]. Thus, CALC gene products are a prototype of 
hormokine mediators and can follow either a classical 
hormonal expression in neuroendocrine cells or a cyto-
kine-like ubiquitous expression pathway in various cell 
types [12]. The inflammatory release of hormokines can 
be induced either directly via microbial toxins (eg, endo-
toxin) or indirectly via a humoral or cell-mediated host 
response (eg, IL-1C, tumor necrosis factor–B, IL-6). The 
induction can be attenuated by cytokines also released 
during a viral infection (eg, interferon-H), which may be 
the reason for the less pronounced increase of PCT in 
viral infections. 
For the diagnosis of infections, the diagnostic accu-
racy of PCT and its optimum cut-offs are completely 
dependent on the use of a sensitive assay in a predefined 
clinical setting. Ideally, an ultrasensitive assay should 
reliably measure circulating concentrations of PCT in all 
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healthy individuals. Such assays are currently available 
for research purposes (PCT-sensitive LIA® [BRAHMS, 
Hennigsdorf, Germany] and N-ProCTKLB) and should be 
widely available for clinicians in the near future. A rapid 
assay assures that results can be timely enough to be 
incorporated into clinical decision making. 
The commercially available Kryptor® PCT assay 
(BRAHMS) takes advantage of a time-resolved ampli-
fied cryptate emission (TRACE) technology. It is 
based on a sheep polyclonal anti-CT antibody and a 
monoclonal antikatacalcin antibody, which bind to 
the CT and katacalcin sequence of CT precursor mol-
ecules. The assay has a functional assay sensitivity of 
0.06 μg/L (ie, three- to 10-fold above normal mean 
values) [13]. Assay time is 19 minutes, and in clinical 
routine, results can be obtained within 1 hour using 
20 to 50 μL of plasma or serum. Another commercially 
available two-site assay (LUMItest® PCT, BRAHMS), 
measures both PCT and the conjoined CT:calcitonin-
carboxypeptide I (CCP I) by means of a luminometer. This 
assay is useful to detect markedly elevated PCT levels in 
severe, systemic bacterial infections (ie, sepsis). However, 
this manual assay has the disadvantage of a relative insen-
sitivity, with an accurate detection limit of approximately 
0.3 to 0.5 μg/L [7,13]. Thus, the LUMItest® assay is not 
sensitive enough to detect mildly or moderately elevated 
PCT levels, which limits its diagnostic use in conditions 
other than overt sepsis. A colorimetric, “quick” bedside 
test, PCT®-Q (BRAHMS), has the advantage of rapid 
determination of circulating CT precursor levels in 30 
minutes. Unfortunately, the assay is only semiquantitative 
and is not sensitive enough to detect moderately elevated 
ProCT levels. 
Procalcitonin as Diagnostic Marker 
for Bacterial Pneumonia 
A variety of studies and reviews have shown the superior 
diagnostic accuracy of PCT as compared to other param-
eters for the diagnosis of sepsis, independent of the origin 
of infection [9,14••,15]. Although the increase of other 
inflammatory markers such as C-reactive protein (CRP) 
is attenuated by immunosuppressive medication (namely 
steroids), the diagnostic accuracy of PCT remains unaffected 
[16]. In addition, PCT seems to have an advantage over CRP 
because of its earlier increase when infection occurs and 
better negative predictive value, which has been shown in 
children with fever of unknown origin [17] or adults in the 
intensive care unit (ICU) with sepsis [14••]. 
The most frequent source of systemic infections is the 
lung [9]. Lower respiratory tract infections (LRTIs) (ie, acute 
bronchitis, acute exacerbations of chronic obstructive lung 
disease or asthma, and pneumonia) account for almost 10% 
of the worldwide burden of morbidity and mortality [18]. As 
much as 75% of all antibiotic doses are prescribed for acute 
respiratory tract infections, in spite of their predominantly 
viral etiology [18]. This excessive use of antibiotics is the 
main cause of the spread of antibiotic-resistant bacteria [19]. 
Thus, decreasing the excess use of antibiotics is essential 
to combat the increase of antibiotic-resistant microorgan-
isms [20]. A reduction of antibiotic use results in fewer 
side effects, lower costs, and in the long-term, decreased 
drug resistance [21]. 
In this context, we conceived and validated a PCT-
guided diagnosis and antibiotic stewardship using cut-off 
ranges in the continuum of LRTIs. In four intervention 
trials enrolling more than 1200 patients, the success of the 























Figure 1. Schematic diagram of CALC I 
expression in adipocytes and thyroidal 
C-cells. In the classic neuroendocrine 
paradigm, the expression of CT-mRNA is 
restricted to neuroendocrine cells, mainly C 
cells of the thyroid. Initially, the 116-amino 
acid prohormone PCT is synthesized and 
subsequently processed to the consider-
ably smaller mature CT. In sepsis and 
inﬂammation, proinﬂammatory mediators 
induce CT-mRNA. In contrast to thyroidal 
cells, parenchymal cells (eg, liver, kidney, 
adipocytes, and muscle) lack secretory 
granules. Hence, unprocessed ProCT is 
released in a nonregulated, constitutive 
manner. In the serum of septic patients, it is 
a peptide of only 114 amino acids, instead 
of 116 amino acids, lacking the N-terminal 
dipeptide alanine-proline. cAMP—cyclic 
adenoside monophosphate; CT—calci-
tonin; IFN—interferon; IL—interleukin; 
Mg—magnesium; mRNA—messenger RNA; 
PCT—procalcitonin; TNF—tumor necrosis 
factor; (Adapted from Muller et al. [12]).
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that if the patient recovered without antibiotics, then there 
was no serious bacterial illness. This circumvented the 
problem of the nonexistent diagnostic gold standard based 
on traditional criteria (eg, clinical signs, CRP, leukocytosis, 
culture result). We compared the routine use of antimicro-
bial therapy versus PCT-guided antimicrobial treatment 
for LRTI. In the PCT group, the physician was advised 
to follow the antibiotic treatment algorithm based on 
the PCT value and the likelihood for bacterial disease 
(Fig. 2) [9,22–24]. 
Thereby, a PCT level less than 0.1 μg/L suggests the 
absence of bacterial infection, and the initiation or con-
tinuation of antibiotics should be strongly discouraged. 
Antibiotic therapy can be considered in critically ill 
patients; that is, in community-acquired pneumonia (CAP) 
patients, those with pneumonia severity index (PSI) class 
V or those with a CURB-65 (ie, confusion, urea nitrogen, 
respiratory rate, blood pressure, 65 years of age and older) 
score greater than three points, chronic obstructive pul-
monary disease (COPD) patients, and those with a GOLD 
(ie, global initiative for chronic obstructive lung disease) 
IV. If antibiotics are given, an early discontinuation of 
antibiotic therapy after 1 to 3 days should be endorsed if 
PCT levels checked daily remain less than 0.1 μg/L.
A PCT level between 0.1 and 0.25 μg/L indicates that 
bacterial infection is unlikely, and the initiation or con-
tinuation of antibiotics should be discouraged. Antibiotic 
therapy can be considered in high-risk patients (ie, PSI IV 
or CURB-65 > 2 in CAP patients; GOLD III or an arterial 
oxygen saturation [SaO2] < 90% after 30 minutes therapy 
on the emergency unit in COPD patients), necrotizing CAP 
(Staphylococcus aureus, Klebsiella pneumoniae, anaero-
bics), critically ill patients suffering from Mycoplasma 
pneumoniae, empyema, and abscesses. 
A PCT level between 0.26 and 0.5 μg/L indicates a pos-
sible bacterial infection, and the initiation or continuation 
of antibiotic therapy should be encouraged. 
A PCT level greater than 0.5 μg/L strongly suggests 
the presence of bacterial infection and antibiotic treat-
ment, and continuation should be strongly encouraged. 
The same cut-offs can be used for patients pretreated 
with antibiotics (ie, treated with one or more doses of anti-
biotics prior to admission to the emergency department). 
In hospitalized patients, PCT levels should be reas-
sessed on days 3, 5, and 7 in patients with ongoing 
antibiotic therapy and in cases of worsening or delayed 
recovery of signs and symptoms. Antibiotics should be 
discontinued using the PCT cut-offs defined above. In 
all patients with a high-peak PCT value (eg, > 1 μg/L), 
discontinuation of antibiotics can already be encour-
aged if levels decrease below 80% to 90% of the 
initial value (eg, stop at 1 μg/L, instead of 0.25 μg/L if 
peak was 10 μg/L).
Persistently elevated PCT levels may indicate a com-
plicated course, but the possibility of falsely high PCT 
levels should be considered [25•]. Conversely, it should 
also be considered that PCT levels may remain relatively 
low in localized infections (eg, empyema, abscess) [25•]. 
Consequently, the PCT algorithm can be overruled 
in patients with immediately life-threatening disease 
(eg, severest comorbidity, emerging ICU need during 
the initial follow-up, hemodynamic or respiratory 
instability, and positive antigen test for legionellosis). 
If the algorithm is overruled and antibiotics are given, 
an early discontinuation of antibiotic therapy after 
3, 5, or 7 days can be more or less endorsed, if PCT 
levels, checked on day 3, 5, and 7 remain less than 










PCT control after 6–24 hours.
AB therapy if:
• Respiratory or hemodynamic   
 instability (ICU admission)
• PCT < 0.1: CAP and PSI V / CURB65  
 > 3, COPD GOLD IV
• PCT 0.1–0.25: CAP with PSI IV and  
 V, CURB65 > 2, empyema,   
 complicated pneumonia, COPD  
 GOLD III, SaO2 < 90% despite 30
 minutes intensive therapy
If on AB therapy, re-evaluate PCT on 
days 3, 5, and 7.
• Stop AB with same cut offs
• Outpatients: AB duration (0–7 days)  
 based on last PCT level
• Initially very high PCT: Stop at   
 80%–90% decrease of peak PCT
Figure 2. Procalcitonin-guided antibiotic 
stewardship. Procalcitonin-guided antibiotic 
therapy was successfully validated in more 
than 1200 patients with lower respiratory 
tract infections in the emergency depart-
ment, primary care, and hospital settings. 
The following cut-off ranges are proposed 
for antibiotic stewardship. AB—antibiotics; 
CAP—community-acquired pneumonia; 
COPD—chronic obstructive pulmonary 
disease; CURB65—confusion, urea nitrogen, 
respiratory rate, blood pressure, 65 years 
of age and older; GOLD—global initia-
tive for chronic obstructive lung disease; 
ICU—intensive care unit; PCT—procal-
citonin; PSI—pneumonia severity index; 
SaO2—oxygen saturation of arterial blood.
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Procalcitonin and Antibiotic Stewardship:
What is the Evidence?
In the first PCT in Respiratory Tract Infections (ProRESP) 
Study, we assessed the capability of the sensitive PCT assay 
(Kryptor® PCT) to identify bacterial LRTIs requiring 
antimicrobial treatment [26••]. The clinical and labora-
tory outcome after a mean of 13 ± 5.4 days was similar in 
both groups. In the PCT group, the percentage of patients 
with LRTI who received antibiotic therapy was reduced 
by 46.6%, compared with the standard group (P < 0.001). 
Antibiotic use could be significantly reduced in all diag-
nostic subgroups, but most strikingly in acute bronchitis 
and acute exacerbations of COPD. 
In patients with CAP, PCT levels were almost always 
high. Pneumonia is defined as inflammation of the 
pulmonary parenchyma, which is often caused by a 
bacterial agent, mirrored in markedly elevated PCT levels. 
In CAP, antimicrobial therapy must be promptly initiated, 
because a delay in treatment is associated with increased 
mortality. Thus, the primary value of PCT in CAP was 
not to reduce antibiotics, but to facilitate the differential 
diagnosis of new or progressing infiltrates. Accordingly, 
PCT guidance could markedly lower the number of anti-
biotic courses in patients with infiltrates on chest x-ray 
unrelated to pneumonia. 
Importantly, the optimal duration of antimicrobial 
therapy in CAP is largely unknown [27]. Most likely, it 
varies from patient to patient and is dependent on, among 
other things, the severity of the disease, the fitness of the 
host response, and the underlying microorganism. Current 
guidelines recommend antibiotic courses of 7 to 14 days, 
depending on illness severity and type of pathogen [28]. 
However, adherence to guidelines is variable [29], and 
physicians tend to treat longer, especially in elderly patients 
with comorbidities and patients with severe CAP [26••]. 
Duration of antibiotic therapy can be guided by clinical 
signs such as defervescence, decrease of sputum produc-
tion and coughing, or improvement of general condition. 
However, the interpretation of the clinical response lacks 
standardization and validation and is prone to inter-
observer variability [30].
The dynamics of PCT levels have prognostic implica-
tions, as persistently elevated levels are associated with 
adverse outcomes [31]. Conversely, decreasing PCT levels 
suggest a favorable outcome, usually showing a log-linear 
drop-off and a half-life of 20 to 24 hours [1]. There-
fore, in the randomized intervention trial, PCT in CAP 
(ProCAP), we assessed the capability of PCT-guidance to 
shorten antibiotic duration in patients with all severity 
levels of CAP admitted to the emergency department. We 
demonstrated in more than 300 patients with CAP that 
PCT guidance allows a safe and marked reduction in the 
duration of antibiotic treatment from a median of 12 to 
5 days with a similar outcome after a clinical follow-up 
of disease status after 6 weeks. Importantly, measures 
of clinical and laboratory outcome were similar in both 
groups [32••]. Thus, PCT appears to be a more reliable 
measure for individual tailoring and early discontinuation 
of antibiotic therapy compared to routinely used clinical 
and laboratory parameters. Only in the PCT group was 
duration of antibiotic courses adapted to the severity of 
CAP. The presence of fever is an important clinical sign 
indicating infection. However, defervescence is of limited 
value to stop antibiotic therapy in view of the up to 40% 
of patients with CAP who present without fever. Similarly, 
in over 70% of patients with CAP of presumed bacterial 
origin, the causative microbe cannot be identified 
[26••,33]. Therefore, culture results are not considered 
central to the clinical care of this infection. This wide 
ambiguity of clinical symptoms and the high rate of nega-
tive culture results could explain the reluctance to stop 
antibiotic therapy early in the control group. Conversely, 
especially if bacteremic, CAP is associated with adverse 
outcomes, and thus, longer antibiotic courses are recom-
mended [34,35]. Accordingly, in the PCT group antibiotic 
therapy was longer in bacteremic patients with a median 
duration of more than 10 days.
In bacterial CAP, delayed initiation of antibiotic 
therapy can be associated with increased mortality. 
Therefore, in the emergency management of suspected 
CAP, antibiotic therapy is rapidly initiated in all patients. 
The presence of nonbacterial diseases is suspected usually 
only after failure of antibiotic therapy, with the ensuing 
risks related to untreated, potentially life-threatening non-
bacterial disease [36]. In self-limiting viral infections, cure 
of CAP under antibiotic therapy may be falsely considered 
as proof of bacterial etiology. In the PCT group, antibiotics 
were withheld from 15% of the patients with suspected 
CAP based on low PCT levels, confirming previous find-
ings [26••]. The uneventful course strongly argues against 
the presence of a clinically relevant bacterial infection in 
these patients. If a patient shows an infiltrate on chest 
radiograph in the presence of acute respiratory symptoms 
and repetitively low PCT levels, clinicians should consider 
watchful waiting or early discontinuation of antibiotic 
therapy and actively seek an alternative diagnosis to bac-
terial pneumonia, including viral pneumonia, pulmonary 
embolism, malignancy, cryptogenic organizing pneu-
monia, and congestive heart failure, among others [37]. 
Conversely, in patients with diagnostic ambiguities, PCT 
levels greater than 0.25 μg/L to greater than 0.5 μg/L 
support the clinician in the diagnosis of CAP. In 
summary, in this study including patients with CAP, PCT 
was a useful marker for the diagnosis and differential 
diagnosis from noninfectious infiltrates and viral infec-
tions and to guide the duration of antibiotics. 
Evidence from Other Studies?
In children admitted with pneumonia, PCT levels had a 
higher sensitivity and specificity to differentiate bacterial 
from viral causes of pneumonia than CRP, IL-6, or leuko-
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cyte count [38]. Ventilator-associated pneumonia (VAP) 
is the most frequent nosocomially acquired infection in 
patients on mechanical ventilation [39]. Bacteriologic cul-
tures including endotracheal aspirates are helpful in the 
diagnosis of VAP; however, complete results often are not 
available within 24 to 48 hours after the sample has been 
taken. Recently, PCT has been used as a complementary 
diagnostic marker for VAP [40]. It is also a useful marker 
for diagnosing VAP in patients with an already triggered 
acute-phase response after successful cardiopulmonary 
resuscitation, where PCT levels were elevated a median 
of 2 days earlier than the clinical diagnosis of VAP [41]. 
However, other studies reported a poor sensitivity for 
PCT in VAP [42,43••]. The problem is that any obser-
vational study investigating the diagnostic accuracy of 
a given marker is biased by the choice of gold standard. 
This gold standard does not exist in infections, and thus, 
all studies are prone to a potential bias. 
For example, soluble triggering receptor expressed on 
myeloid cells (sTREM-1) has been put forward for diagno-
sis and outcome prediction in patients with sepsis, namely 
due to CAP and VAP [44]. Analyzing circulating levels of 
sTREM-1 in our asserved samples from the ProCAP study 
revealed unexpected inaccuracies of this marker for the 
routine use of CAP [45]. Circulating sTREM-1 levels were 
not helpful for the assessment of etiology and severity in 
patients with CAP or in predicting outcome of the disease. 
We found no significant correlation between sTREM-1 
levels, independent if assessed with the use of immunoblot 
technique or enzyme-linked immunosorbent assay using 
several antibodies (from R&D Systems, Minneapolis, 
MN, and others), before and after ultracentrifugation, in 
plasma or serum, respectively. Similarly, sTREM-1 concen-
trations did not correlate with other markers of infection:
CRP (r = 0.03, P = not significant), PCT (r = -0.03, 
P = not significant) and leukocyte count (r = 0.03, 
P = not significant). Conversely, measurement of the 
local production of sTREM-1 in bronchoalveolar fluid 
might provide more reliable results [46]. This, however, 
is not a cost-efficient approach in the routine care of 
patients with CAP.
Interventional studies, in which the antimicrobial 
therapy is guided by PCT and in which the gold standard 
is the outcome, have the potential to resolve this dilemma. 
No marker other than PCT has been rigorously assessed 
in intervention studies for its capability to be used safely 
for antibiotic stewardship, the ultimate proof for its 
diagnostic accuracy. In the context of VAP, intervention 
studies are still lacking, including for PCT [47]. The time 
has arrived to move beyond the observational reporting of 
“promising” biomarkers [48]. Specific cutoff ranges must 
be proposed and intervention studies conducted. Only this 
will open our eyes and reveal if biomarkers can really help 
us in the routine care of patients with pneumonia, LRTIs, 
and ultimately sites of infection other than the lung. 
Procalcitonin as Prognostic Marker in CAP?
Another pivotal aspect in CAP is to be able to predict 
its prognosis and estimate its severity for guiding thera-
peutic options such as the need for hospital or intensive 
care admission, suitability for discharge, and choice and 
route of antimicrobial agents. PSI is a widely accepted 
and validated severity scoring system that assesses the 
risk of mortality for pneumonia patients in a two-step 
algorithm [49]. However, its complexity is high, jeopar-
dizing its dissemination and implementation, especially 
in everyday practice. Therefore, the CURB-65 score has 
been proposed as a simpler alternative [50]. Addition-
ally, various easy-to-determine surrogate biomarkers 
have been proposed to predict disease severity in CAP 
patients, thereby aiming to complement PSI [51–53]. 
The prognostic value of PCT in CAP and VAP patients 
has therefore been investigated in several studies. 
Boussekey et al. [54] showed that the kinetics of PCT 
when increasing from day 1 to day 3 in severe CAP indi-
cated a poor prognosis. Conversely, a PCT level less than 
0.95 μg/L on day 3 in intubated patients was associated 
with a favorable outcome [54]. Similarly, higher PCT 
concentrations were associated with the development of 
complications and with death [52]. The kinetics of PCT 
proved also to be a useful prognostic marker in patients 
with VAP [43••,55]. 
In our study, PCT showed better prognostic accuracy 
compared to routinely measured parameters like CRP 
or leukocyte count and has therefore been proposed as a 
marker of disease severity [32••,52,56]. However, a wide 
overlap existed in PCT levels between different severities 
of CAP and only a small difference in PCT levels between 
survivors and nonsurvivors of CAP. Based on these data, 
PCT seems to be rather a reliable diagnostic marker to 
guide decisions on antibiotic therapy and not an ideal 
prognostic tool [25•,32••]. However, the prognostic accu-
racy of PCT can be markedly improved considering the 
course of PCT [57]. Jensen et al. [57] analyzed 3642 PCT 
measurements in 472 critically ill patients. PCT and espe-
cially the PCT increase within 1 day was an independent 
predictor of 90-day all-cause mortality in a multivari-
ate Cox regression analysis model. The adjusted hazard 
ratio for the PCT increase for 1 day was 1.8 (95% CI, 
1.3–2.7) and the relative risk for mortality in the ICU for 
patients with an increasing PCT was, after 1 day increase, 
1.8 (95% CI, 1.4–2.4), after 2 days increase, 2.2 (95% 
CI, 1.6–3), and after 3 days increase, 2.8 (95% CI, 
2–3.8). Thus, a PCT increase during the course of disease 
was an independent predictor of all-cause mortality in a 
90-day follow-up period after ICU admission. Levels or 
increases in CRP and leukocyte count did not seem to 
predict mortality. Interestingly, other recently evaluated 
hormone levels show better prognostic accuracy to predict 
survival and outcome in patients with CAP as compared 
to PCT [58–60]. 
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Procalcitonin and Pneumonia:
Some Words of Caution
The likelihood for bacterial infections increases with 
increasing PCT levels. Therefore, we propagate the use 
of cut-off ranges for the diagnosis of bacterial infections 
and antibiotic stewardship in several intervention trials. 
It cannot be overemphasized that the diagnostic accuracy 
of PCT and its optimal cut-offs are completely dependent 
on the use of a sensitive assay in an appropriate clinical 
setting with a pretest probability for the presence of a 
specific infection. PCT is never a substitute for a careful 
history and physical examination. A clinician should resist 
the temptation to rely solely on the result of a laboratory 
test rather than a demanding clinical examination.
As is the case for all diagnostic tests, a PCT level must 
always be evaluated and re-evaluated during follow-up, 
with proper regard to the clinical context. Importantly, 
circulating PCT levels can be increased in noninfectious 
conditions, such as severe mechanical or surgical trauma, 
chemical pneumonitis, severe burns, or heat strokes [25•] 
and may remain relatively low even in sepsis induced by 
bacterial infections [22,24,61]. Falsely low PCT levels are 
typically seen during the early course or localized state 
of an infection and must be considered in patients with 
suspected complications of CAP (ie, empyema). PCT 
levels in these patients often show a gradual increase 
during follow-up measurements after 6 to 24 hours and 
thereby point to an underlying bacterial disease. Again, 
this stresses the importance of follow-up measurements. 
Conclusions
An ideal marker for pneumonia should allow an early 
diagnosis and a differential diagnosis from noninfectious 
or viral conditions, and it should inform about the course 
and prognosis of the disease. PCT covers these features 
better than other markers, namely CRP, leukocyte count, 
and proinflammatory cytokines [14••]. PCT has emerged 
as a reliable diagnostic marker of pneumonia. A PCT-
based therapeutic strategy can reduce antibiotic usage, 
mainly by reducing the duration of antibiotic courses, 
by using a new rapid and sensitive assay. However, PCT 
should not be used uncontrolled as a substitute for a care-
ful clinical assessment. Especially, falsely low PCT levels 
must be considered in patients with localized infections 
and in the context of pneumonia especially in patients 
with empyema.
The prognostic accuracy of PCT proved to be better 
than routinely available parameters. However, other 
biomarkers, namely proadrenomedullin and natriuretic 
peptides, are even more promising in this respect. There-
fore, PCT should be considered a diagnostic parameter 
able to reduce and guide antibiotic use, whereas novel bio-
markers might guide prognostic decision making, improve 
the allocation of healthcare resources, and reduce hospi-
talization costs.
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